Investor Relations

AcuityBio is a privately-held company based in the Greater Boston area. Early research was supported by the Center for Integration of Medicine and Innovative Technology (CIMIT), the American College of Surgeons, and the Wallace H. Coulter Foundation. In 2008, the company was awarded two Small Business Innovation Research grants from the National Cancer Institute. AcuityBio was recently awarded a Qualifying Therapeutic Discovery Program grant from the IRS for continuing work devoted towards commercializing our lead product.


AcuityBio is commercializing a first in class therapeutic drug delivery technology, which has wide applicability. We are focused on developing a drug eluting implant to treat residual occult tumors left behind after surgical resection in the large, untapped early stage non-small cell lung cancer market. We are moving our first product candidate through a carefully planned preclinical program in preparation for pilot safety trials. AcuityBio is actively seeking strategic joint collaborative development partners.


Please contact CEO - Chairman John "Jay" Schwartz at jay@acuitybio.com if you are interested in learning more information.